Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adhansia XR vs Concerta in ADHD (RE-DAX)
NCT04507204Phase 4Terminated
- Sponsor
- Purdue Pharma
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Purdue Pharma. Primary endpoint: ADHD Rating Scale 5 Total Score at Month 2. Started Jul 2020; status: terminated.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04507204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507204.